<DOC>
	<DOCNO>NCT00790647</DOCNO>
	<brief_summary>RATIONALE : Giving melphalan bortezomib stem cell transplant stop growth abnormal cell stop divide kill . Giving colony-stimulating factor certain chemotherapy drug , help stem cell move bone marrow blood collect store . Chemotherapy monoclonal antibody therapy give prepare bone marrow stem cell transplant . The stem cell return patient replace blood-forming cell destroy chemotherapy . PURPOSE : This phase II trial study well give melphalan together bortezomib follow stem cell transplant work treat patient primary systemic amyloidosis .</brief_summary>
	<brief_title>Melphalan , Bortezomib , Stem Cell Transplant Treating Patients With Primary Systemic Amyloidosis</brief_title>
	<detailed_description>OBJECTIVES : - To determine hematologic response high-dose melphalan autologous stem cell transplantation increase addition bortezomib condition regimen patient primary systemic amyloidosis . OUTLINE : - Autologous stem cell mobilization collection : Patients receive filgrastim mobilize stem cell , collect . - Conditioning regimen : Patients receive bortezomib intravenously day -6 , -3 , 1 , 4 oral high-dose melphalan day -2 -1 . - Stem cell transplantation : Patients undergo autologous stem cell transplantation day 0 . After completion study therapy , patient follow every 6 month 1 year annually thereafter .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Inclusion criterion : DISEASE CHARACTERISTICS : Histologically confirm primary systemic amyloidosis base follow criterion : Amyloid lightchain disease Deposition amyloid material congo red stain show characteristic green birefringence Monoclonal light chain protein ( Bence Jones protein ) serum urine , immunohistochemical study , serum free light chain assay Evidence tissue involvement carpal tunnel syndrome ( i.e. , positive immunohistochemical stain bone marrow demonstrate clonal plasma cell ) ; tissue amyloid deposit antikappa antilambda antiserum ; evidence plasma cell dyscrasia serum/urine bone marrow ; overwhelmingly convince clinical feature ( e.g. , macroglossia ) associate systemic manifestation PATIENT CHARACTERISTICS : Southwest Oncology Group performance status 01 Fertile patient must use effective contraception Left ventricular ejection fraction ≥ 45 % Echocardiogram within past 60 day diffusion capacity lung carbon monoxide ≥ 50 % PRIOR CONCURRENT THERAPY : Prior chemotherapy alkylating agent allow provide morphological cytogenetic evidence myelodysplastic syndrome Prior total cumulative dose oral melphalan &lt; 300 mg At least 4 week since prior cytotoxic therapy fully recover Exclusion criterion : No senile , secondary , localize , dialysisrelated , familial amyloidosis No overt multiple myeloma ( &gt; 30 % bone marrow plasmacytosis , extensive [ &gt; 2 ] lytic lesion , hypercalcemia ) Not pregnant nursing No myocardial infarction within past 6 month , congestive heart failure , arrhythmia refractory therapy No prior malignancy except follow : Adequately treat basal cell squamous cell skin cancer In situ cervical cancer Adequately treat stage I II cancer currently complete remission Any cancer patient diseasefree ≥ 5 year No advance ( grade 34 ) preexist neuropathy No HIV positivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>primary systemic amyloidosis</keyword>
</DOC>